14. Murakami K, Kubota SI, Tanaka K, Tanaka H, Akabane K, Suzuki R Shinohara Y, Takei H, Hashimoto S, Tanaka Y, Hojyo S, Sakamoto O, Naono N, Takaai T, Sato K, Kojima Y, Harada T, Hattori T, Fuke S, Yokota I, Konno S, Washio T, Fukuhara T, Teshima T, Taniguchi M, Murakami M. High-precision rapid testing of omicron SARS-CoV-2 variants in clinical samples using AI-nanopore. Lab Chip. 23(22): 4909-4918, 2023.
13. Kimura I, Yamasoba D, Nasser H, Ito H, Zahradnik J, Wu J, Fujita S, Uriu K, Sasaki J, Tamura T, Suzuki R, Deguchi S, Plianchaisuk A, Yoshimatsu K, Kazuma Y, Mitoma S, Schreiber G, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Shirakawa K, Takayama K, Irie T, Hashiguchi T, Nakagawa S, Fukuhara T, Saito A, Ikeda T, Sato K. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics. J Virol. 97(10): e0101123, 2023.
12. Ichikawa T,Tamura T, Takahata M, Ishio T, Ibata M, Kasahara I, Minauchi K, Yamamoto S, Teshima T, Fukuhara T. Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: A prospective study. Br J Haematol. in press, 2023.
11. Kimura M, Matsuoka R, Taniguchi S, Maruyama J, Paessler S, Oka S, Yamashita A, Fukuhara T, Matsuura Y, Tani H. Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus. Virology. 587: 109867, 2023.
10. Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, Kazami Y, Washizaki A, Masuta Y, Suzuki R, Matsuda K, Komori M, Morey AL, Ishimoto K, Nakata M, Hasunuma T, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Sato N. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. Cell Rep Med. 4(8):101134,2023.
9. Tamura T, Yamasoba D, Oda Y, Ito J, Kamasaki T, Nao N, Hashimoto R, Fujioka Y, Suzuki R, Wang L, Ito H, Kashima Y, Kimura I, Kishimoto M, Tsuda M, Sawa H, Yoshimatsu K, Yamamoto Y, Nagamoto T, Kanamune J, Suzuki Y, Ohba Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Yokota I, Matsuno K, Takayama K, Tanaka S, Sato K, Fukuhara T. Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5. Commun Biol. 6(1): 772, 2023.
8. Fujita S, Uriu K, Pan L, Nao N, Tabata K, Kishimoto M, Itakura Y, Sawa H, Kida I, Tamura T; Genotype to Phenotype Japan (G2P-Japan) Consortium; Fukuhara T, Ito J, Matsuno K, Sato K. Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model. J Infect Dis. 228(8): 1060-1065, 2023.
7. Tomiyama T, Suzuki R, Harada N, Tamura T, Toshida K, Kosai-Fujimoto Y, Tomino T, Yoshiya S, Nagao Y, Takeishi K, Itoh S, Kobayashi N, Ito H, Yoshio S, Kanto T, Yoshizumi T, Fukuhara T. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients. Front Cell Infect Microbiol. 13: 1197349, 2023.
6. Komori M, Nogimori T, Morey AL, Sekida T, Ishimoto K, Hassett MR, Masuta Y, Ode H, Tamura T, Suzuki R, Alexander J, Kido Y, Matsuda K, Fukuhara T, Iwatani Y, Yamamoto T, Smith JF, Akahata W. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern. Nat Commun. 14(1): 2810, 2023.
5. Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, Nao N, Itakura Y, Deguchi S, Suzuki R, Wang L, Begum MM, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Shimizu R, Tsuda M, Kosugi Y, Fujita S, Pan L, Sauter D, Yoshimatsu K, Suzuki S, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Schreiber G, Maenaka K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Fukuhara T, Saito A, Tanaka S, Matsuno K, Takayama K, Sato K. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 14(1): 2800, 2023.
4. Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, Kida I, Nasser H, Shofa M, Begum MM, Tsuda M, Oda Y, Suzuki T, Sasaki J, Sasaki-Tabata K, Fujita S, Yoshimatsu K, Ito H, Nao N, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Kuramochi J, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Saito A, Matsuno K, Takayama K, Hashiguchi T, Tanaka S, Fukuhara T, Ikeda T, Sato K. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat Commun. 14(1): 2671, 2023.
3. Torii S, Kim KS, Koseki J, Suzuki R, Iwanami S, Fujita Y, Jeong YD, Ito J, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K, Matsuura Y, Shimamura T, Iwami S, Fukuhara T. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLoS Pathog. 19(3): e1011231, 2023.
2. Hashimoto R, Tamura T, Watanabe Y, Sakamoto A, Yasuhara N, Ito H, Nakano M, Fuse H, Ohta A, Noda T, Matsumura Y, Nagao M, Yamamoto T, Fukuhara T,Takayama K. Evaluation of Broad Anti-Coronavirus Activity of Autophagy-Related Compounds Using Human Airway Organoids. Mol Pharm. 20(4): 2276-2287, 2023.
1. Nakajima S, Ohashi H, Akazawa D, Torii S, Suzuki R, Fukuhara T, Watashi K. Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication. Viruses. 15(2): 452, 2023.